Neochord
Minneapolis, Minnesota, United States · Biotechnology, Health Care, Manufacturing · 20 employees
NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation. The company is dedicated to advancing the treatment of mitral regurgitation and developing innovative therapies for degenerative mitral valve disease.
Funding history
- Seed — $493K — Mar 2025
- Seed — $914K — Aug 2024
- Seed — $4.6M — Jul 2023
- Seed — $2.9M — Nov 2022
- Seed — $2.9M — Sep 2022
Recent signals
- Mar 13, 2025: Raised $493K in Seed
- Aug 29, 2024: Raised $914K in Seed
- Feb 29, 2024: NeoChord Appoints Todd Berg as Chief Executive Officer
- Feb 22, 2024: NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
- Jul 05, 2023: Raised $4.6M in Seed
- Nov 14, 2022: Raised $2.9M in Seed
- Sep 22, 2022: Raised $2.9M in Seed
- Mar 08, 2022: Raised $1.8M in Seed
See plans & pricing → Track Neochord’s funding, hiring, and signals — with verified contacts — on Fundz.